A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma

John M. Kirkwood, Rene Gonzalez, Douglas Reintgen, Philip R. Clingan, Robert R. McWilliams, Dinesh P. De Alwis, Annamaria Zimmermann, Michael P. Brown, Robert L. Ilaria, Michael J. Millward

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences